---
title: "BTBP: Recently officially launched Phase III clinical trials for human prothrombin complex"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262017471.md"
description: "BTBP announced that its subsidiary has officially launched the Phase III clinical trial of human prothrombin complex, which is used to treat various coagulation factor deficiencies. Although similar products are already available in domestic and international markets, this product still needs to complete clinical trials and market application, and investors should be aware of the associated risks"
datetime: "2025-10-21T09:34:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262017471.md)
  - [en](https://longbridge.com/en/news/262017471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262017471.md)
generator: "portal-rs"
---

# BTBP: Recently officially launched Phase III clinical trials for human prothrombin complex

BTBP announced that its subsidiary, China National Pharmaceutical Group Wuhan Biological Products Co., Ltd., has completed the clinical ethical review and preparations for clinical enrollment for the human prothrombin complex it developed, and has officially launched Phase III clinical trials recently. This product is mainly used for the treatment of congenital and acquired deficiencies of coagulation factors II, VII, IX, and X, including Hemophilia B, anticoagulant overdose, and vitamin K deficiency. Currently, several companies in the domestic market produce this product, and there are also several multinational companies producing it in the international market. However, this product still needs to complete Phase III clinical trials and submit a drug marketing authorization application, among other procedures, and there are many internal and external uncertainties. Investors are advised to pay attention to investment risks

### Related Stocks

- [600161.CN](https://longbridge.com/en/quote/600161.CN.md)

## Related News & Research

- [CMOC Group Declares Interim Dividend and Details Tax Arrangements for H Shareholders](https://longbridge.com/en/news/296383667.md)
- [Inside OpenAI's plan to make ChatGPT the way you use your computer](https://longbridge.com/en/news/296462542.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [HELP Therapeutics Announces Nature Medicine Has Published HiCM-188 Clinical Trial Data for Advanced Ischemic Heart Failure](https://longbridge.com/en/news/296448083.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**